The Association Between Psoriasis and Intestinal Bacterial Population

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02417792

Acronym

PIB

Enrollment

Registered

2015-04-16

Start date

2015-05-14

Completion date

2019-02-18

Last updated

2019-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Keywords

psoriasis, microbiota

Brief summary

At least 20 psoriasis patients will be compared to at least 20 participants without psoriasis Bacterial genomic DNA will be extracted from stool samples of participants. The intestinal bacterial populations will be compared in order to examine whether there are differences between the groups.

Detailed description

Intestinal bacterial population has a significant influence on health and sickness conditions. It affects the development and the function of the immune system (Th2, Th1 or Th17) by bacterial protein expression and by the composition of the bacterial population. Psoriasis is an immune related dermal disease. The trigger for this disease is currently unknown but, it is possible that intestinal bacteria are a factor in its development. Study design: Participants will be divided into 3 groups: * Psoriasis patients treated with topical medications * Psoriasis patients treated with IV or sub-cutaneous medications (e.g biological medications) * Healthy participants (control group) Bacterial genomic DNA will be extracted from stool samples of participants. The intestinal bacterial populations will be compared in order to examine whether there are differences between the groups.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* Dermal psoriasis patients diagnosed by a dermatologist.

Exclusion criteria

* Treatment with antibiotics or probiotics within the prior 3 months. * incapable of signing an inform concent.

Design outcomes

Primary

Measure	Time frame	Description
A significant change (P<0.05) in enteric bacterial composition of psoriasis patients (n=20) vs controls (n=20) as assessed by alpha diversity, beta diversity and taxonomic analysis.	2 years	To examine whether fecal bacterial populations of psoriasis patients (not treated by enteral medications) are different compared to healthy participants

Outcome results